{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:35:56Z","timestamp":1746185756552},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10096-022-04427-2","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T10:03:32Z","timestamp":1650967412000},"page":"977-979","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dalbavancin in clinical practice: a particular place for the elderly?"],"prefix":"10.1007","volume":"41","author":[{"given":"Chlo\u00e9","family":"Wackenheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Le Mar\u00e9chal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Pluchart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebtan","family":"Gavazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvan","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pavese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"GRIC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"issue":"4","key":"4427_CR1","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J (2015) Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 59(4):1849\u20131855","journal-title":"Antimicrob Agents Chemother avr"},{"key":"4427_CR2","doi-asserted-by":"publisher","unstructured":"Leuthner K, Buechler K, Kogan D, Saguros A, Lee S (2016) Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag 931\u201340.\u00a0https:\/\/doi.org\/10.2147\/TCRM.S86330","DOI":"10.2147\/TCRM.S86330"},{"issue":"4","key":"4427_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","volume":"36","author":"D Knafl","year":"2017","unstructured":"Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F (2017) Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 36(4):677\u201380","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"4","key":"4427_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","volume":"51","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE (2018) Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016). Int J Antimicrob Agents avr 51(4):608\u2013611","journal-title":"Int J Antimicrob Agents avr"},{"key":"4427_CR5","unstructured":"US Food and Drug Administration (FDA). DALVANCETM highlights of prescribing information. Reference ID: 4296015"},{"issue":"8","key":"4427_CR6","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1128\/AAC.00274-15","volume":"59","author":"SP McCurdy","year":"2015","unstructured":"McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW (2015) In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother ao\u00fbt 59(8):5007\u20135009","journal-title":"Antimicrob Agents Chemother ao\u00fbt"},{"issue":"4","key":"4427_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodr\u00edguez-Gonz\u00e1lez C et al (2018) Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents avr 51(4):571\u2013577","journal-title":"Int J Antimicrob Agents avr"},{"issue":"3","key":"4427_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/1120009X.2017.1404277","volume":"30","author":"F Arena","year":"2018","unstructured":"Arena F, Romanini E, Rosi E, Salomone C, Tucci G, Pempinello C et al (2018) The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. J Chemother 30(3):131\u20139","journal-title":"J Chemother."},{"issue":"2","key":"4427_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","volume":"39","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S (2016) Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf f\u00e9vr 39(2):147\u2013157","journal-title":"Drug Saf f\u00e9vr"},{"issue":"5","key":"4427_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","volume":"54","author":"A Dinh","year":"2019","unstructured":"Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A et al (2019) French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents 54(5):668\u2013672","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"4427_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C et al (2018) Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis 67(5):795\u20138","journal-title":"Clin Infect Dis."},{"issue":"10","key":"4427_CR12","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V et al (2008) A manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients: validation of modified CIRS guidelines. J Am Geriatr Soc 56(10):1926\u20131931","journal-title":"J Am Geriatr Soc"},{"key":"4427_CR13","unstructured":"Comit\u00e9 de l\u2019Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie (CA- SFM); European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommandations [in French]"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04427-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04427-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04427-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T12:12:00Z","timestamp":1653567120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04427-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4427"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04427-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted in accordance with the Declaration of Helsinki as well as national and institutional standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}